NCT02372630View on ClinicalTrials.gov

The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 23, 2014

Primary Completion Date

February 1, 2018

Study Completion Date

May 1, 2018

Conditions
Type 2 Diabetes
Interventions
DRUG

Linagliptin

5 mg daily oral tablets of linagliptin

DRUG

Placebo

matching placebo giving orally daily

Trial Locations (1)

14215

ECMC Ambulatory Center, 3rd Floor, Buffalo

Sponsors

Collaborators (1)

Kaleida Health
All Listed Sponsors
collaborator

Kaleida Health

OTHER

lead

University at Buffalo

OTHER

NCT02372630 - The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects | Biotech Hunter | Biotech Hunter